| Date YYYY-MM-DD |
Board Meeting | Decision Point Number | Title |
|---|---|---|---|
| 2023-05-10 | B49 | GF/B49/DP01 |
Approval of the Agenda Approval of the Agenda
<p>The Agenda for the 49th Board Meeting (GF/B49/01-Revision 1) is approved.</p>
|
| 2023-05-10 | B49 | GF/B49/DP02 |
Approval of the Rapporteur Approval of the Rapporteur
<p>Mohamed Chakroun from the Eastern Mediterranean Region is designated as Rapporteur for the 49th Board Meeting.</p>
|
| 2023-05-10 | B49 | GF/B49/DP03 |
2023-2028 KPI Framework adjustments 2023-2028 KPI Framework adjustments
<p>The Board notes the recommendations of the Audit and Finance Committee (“AFC”) as set forth in GF/AFC21/EDP02, and the Strategy Committee (“SC”) as set forth in GF/SC21A/DP01, and:</p>
<ol type="i">
<li>Approves the adjustments to the 2023-2028 Key Performance Indicator (“KPI”) Framework (including each KPI) as set forth in GF/B49/03 Annex 2;</li>
<li>Notes that proposed material changes to a KPI (refer to GF/B49/03 Annex 1 for the approach to assessing materiality) will continue to be recommended by the AFC or SC, within their respective allocated responsibilities (each a “Relevant Committee”) (as set forth in Annex 2 section 2.2 of GF/AFC20/09 and Annex 2 section 2.1 of GF/SC20/05 revision 2), for Board approval; and</li>
<li>Delegates authority to the Secretariat, in consultation with the Relevant Committee Chair and Vice Chair, to make non-material KPI adjustments, in line with GF/B49/03 Annex 1, and report back to the Relevant Committees and Board on all such changes.</li>
</ol>
|
| 2023-05-11 | B49 | GF/B49/DP04 |
Amended Risk Appetite Statements Amended Risk Appetite Statements
<ol>
<li>The Board:
<ol type="i">
<li>recalls its ultimate responsibility to the Global Fund’s stakeholders for overseeing the implementation of effective risk management;</li>
<li>affirms the Strategy Committee’s concurrence with the amended Risk Appetite Statements under such committee’s oversight, as reported to the Audit and Finance Committee; and</li>
<li>further affirms the Audit and Finance Committee’s concurrence with the amended Risk Appetite Statements under such committee’s oversight and integration of the Strategy Committee’s concurrence, as set forth in Annex 1 to GF/AFC21/06 and pursuant to decision point GF/AFC21/DP01.</li>
</ol>
</li>
<li>Based upon the recommendation of the Audit and Finance Committee, the Board approves the amended Risk Appetite Statements, including risk appetite and timeframes to achieve target risk, as set forth in the table in Annex 1 to GF/B49/04, acknowledging that the target risk level for each risk shall become the revised risk appetite at the target due date, or when earlier achieved.</li>
<li>This decision point and the amended Risk Appetite Statements approved by it shall supersede decision point GF/B46/DP05 (November 2021).</li>
</ol>
|
| 2023-05-11 | B49 | GF/B49/DP05 |
Appreciation of Outgoing Chair and Vice-Chair of the Board Appreciation of Outgoing Chair and Vice-Chair of the Board
<p>The Board expresses its deep appreciation to Dr. Donald Kaberuka for his leadership as Chair of the Board. Over his time working with the Global Fund, he has driven strong engagement for the Global Fund at the most senior levels, provided strategic direction including during a prolonged period of virtual governance, and demonstrated clear commitment to the work of the Global Fund.</p>
<p>The Board also expresses sincere gratitude to Lady Roslyn Morauta for her leadership as Vice-Chair of the Board. She has served the Global Fund with passion and dedication and continues to show her personal conviction for the mission of the Global Fund by her willingness to continue as the incoming Chair of the Board. During her tenure as Vice-Chair, Lady Roslyn Morauta has been an active leader and a strong advocate for the Global Fund and the communities we serve.</p>
<p>During their tenure, Dr Kaberuka and Lady Morauta presided over strategy deliberations and decisions that will continue to shape the future of the Global Fund under its new strategy. Together, they have contributed to strengthening relations among Global Fund stakeholders. Their contribution will have a lasting impact on the Global Fund.</p>
<p>The Board wishes Dr Kaberuka every success in the future and bestows upon him the honorary title of Chair Emeritus. The Board welcomes Lady Roslyn Morauta into her new role, and looks forward to her tenure, as Chair of the Board.</p>
|
| 2023-07-19 | B49 | GF/B49/EDP01 |
Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B49/ER01 (“Table 1”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2023-06-30 | B49 | GF/B49/EDP02 |
Appointment of Replacement Member on the Strategy Committee Appointment of Replacement Member on the Strategy Committee
<p>The Board approves the appointment of:</p>
<ol>
<li>Jérôme Salomon, representing the World Health Organization Constituency, as a non-voting member of the Strategy Committee for a term that will expire on May 2025, or until the appointment of his successor.</li>
</ol>
|
| 2023-06-09 | B49 | GF/B49/EDP03 |
Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for the grant listed in Table 1 of GF/B49/ER03 (“Table 1”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2023-08-07 | B49 | GF/B49/EDP04 |
Approval of the Report of the 49th Board Meeting Approval of the Report of the 49th Board Meeting
<p>The Board approves the Report of the 49th Board Meeting, as set forth in GF/B49/18.</p>
|
| 2023-08-21 | B49 | GF/B49/EDP05 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B49/ER05 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2023-10-17 | B49 | GF/B49/EDP06 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B49/ER06 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2023-10-17 | B49 | GF/B49/EDP07 |
Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B49/ER06 (“Table 2”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2023-11-01 | B49 | GF/B49/EDP08 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B49/ER07 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2023-11-01 | B49 | GF/B49/EDP09 |
Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period Decision on the Secretariat’s Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period
<p>The Board:</p>
<ol>
<li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B49/ER07 (“Table 2”);</li>
<li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2023-11-09 | B49 | GF/B49/EDP10 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B49/ER08 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2023-11-13 | B49 | GF/B49/EDP11 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B49/ER09 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li>
</ol>
|
| 2023-11-13 | B49 | GF/B49/EDP12 |
Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2023-2025 Allocation
<p>The Board:</p>
<ol>
<li>Approves the funding recommended for each country disease component, and its constituent grants, as <br />listed in Table 1 of GF/B49/ER10 (“Table 1”);</li>
<li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li>
<li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li>
<li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the <br />“TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li>
</ol>
|